Cancer Cause and Prevention Research — CFDA 93.393

Cause-and-prevention obligations at $5.92 billion

USAspending.gov records $5,915,477,684.62 in obligations under CFDA 93.393. Two thousand four hundred ninety-seven awards produce that stock. A simple average is about $2.37 million per award — typical of multi-year research grants rather than state block grants. That average is a quotient of two packet totals, not a typical project budget.

The assistance-listing title is CANCER CAUSE AND PREVENTION RESEARCH. CFDA 93.393 is the identifier. Cancer biology or treatment listings, if tagged under other CFDA numbers, are not included in the $5.92 billion.

USAspending.gov records the $5,915,477,684.62 obligation stock for CFDA 93.393 together with 2,497 awards, 341 recipients, and 48 states. Keep cause-and-prevention research on 93.393 when quoting these four facts. Outlays remain a separate column.

Hundreds of recipients, 48 states

Three hundred forty-one recipients share 2,497 awards, or about 7.3 award records per recipient on average. Splitting $5.92 billion evenly would assign about $17.3 million per recipient. Universities and institutes are the unit this kind of listing usually names; the packet does not list the 341.

Forty-eight states in the geographic count show broad coding without covering every coded jurisdiction. Research dollars still concentrate at large biomedical campuses. Place-of-performance amounts are on the program table.

Award count is not a study count

Among research listings, 93.393 is a dense file: 2,497 rows against 341 recipients. Renewals and supplements can inflate award count relative to unique projects. Award count is a weak proxy for “number of prevention studies.” Recipients (341) are the organizational headcount.

The packet does not report publication counts, trial enrollments, or incidence. Citing 2,497 as papers or patients would be a unit error. Keep the units straight: dollars, awards, recipients, states.

Obligations versus research outlays

The $5.92 billion is an obligation total from USAspending.gov. Outlays — cash paid against these research awards — are not in the packet. A laboratory can show a large obligation stock while draws follow a multi-year grant calendar. Deobligations and upward adjustments both move the total.

Use CFDA 93.393 to size this cause-and-prevention listing. Do not use it as a scientific-progress scorecard. This page reports the obligation book tagged 93.393.

What the 93.393 tables omit

The Cancer Cause and Prevention Research hub lists award-backed obligations from USAspending.gov. It is not a publication index, not a trial registry, and not a patient census. Series that never appear as assistance awards will not show up in the $5,915,477,684.62.

Place-of-performance on 48 states is a coding field. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already spent on reagents or staff.

Where the 93.393 table lives

The Cancer Cause and Prevention Research program page overlays these four facts. The all-programs index ranks 93.393 among other assistance listings. Agency pages show awarding-agency rollups. For 93.393 only, start on the program page.

CFDA 93.393’s 2,497 awards spread $5,915,477,684.62 across 341 recipients and 48 states. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 7.3 award records per recipient is the density story. Outlays remain a separate column. Source: USAspending.gov assistance awards. The four-fact citation for CFDA 93.393 is the obligation stock on this extract, together with the award, recipient, and state counts already named above. Do not convert those figures into outlays, and do not treat award count as a service census. Start on the program page for CFDA 93.393 before ranking this listing against other assistance rows. Obligations remain the reporting concept on this extract; outlays are not stored in the packet facts. Award count is a record count; recipient count is the organizational headcount; the state figure is a coded-jurisdiction count from USAspending.gov. Deobligations and upward adjustments both move the obligation stock; this page does not publish remaining balances. Internal links on this overlay point to the program page, the all-programs index, and agency rollups. SpendingVault indexes USAspending.gov assistance awards; it does not convert this CFDA into a performance scorecard. If a number you expected is missing, the usual cause is a different reporting concept than obligations on assistance awards.

Questions

How much is obligated for cancer cause and prevention research?

USAspending.gov records $5,915,477,684.62 in obligations for CFDA 93.393. SpendingVault indexes 2,497 awards, 341 recipients, and 48 states. The figure is an obligation sum, not an outlay and not a study count. CFDA 93.393’s $5.92 billion is the USAspending obligation stock.

How many awards does CFDA 93.393 carry?

The listing shows 2,497 awards against 341 recipients, or about 7.3 award records per recipient. A simple average is about $2.37 million per award. Award count is not a publication or patient count. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.

How many organizations receive these awards?

The extract lists 341 recipients on assistance awards tagged 93.393. Geographic coding covers 48 states. The packet does not name the 341 or publish scientific output. Recipient count is the organizational headcount. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.

Is $5.92 billion already spent on prevention research?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.393’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn or research results. The $5.92 billion on 2,497 awards is the obligation figure. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.